dr. woyach on 3-year follow-up of acalabrutinib/obinutuzumab combo in cll
Published 5 years ago • 197 plays • Length 1:20Download video MP4
Download video MP3
Similar videos
-
1:11
acalabrutinib-obinutuzumab in cll: 3-year follow-up
-
1:39
dr. woyach on the role of acalabrutinib in cll
-
1:03
dr. woyach on the safety of acalabrutinib versus ibrutinib in cll
-
1:47
dr. woyach on ibrutinib resistance in cll
-
6:34
3-year follow-up of obinutuzumab, ibrutinib and venetoclax for cll
-
1:05
dr. woyach on the utility of time-limited therapies in cll
-
1:25
dr. woyach on the role of chemoimmunotherapy in cll
-
0:55
dr. woyach on the results of the elevate-tn trial
-
2:30
ascend: 3 year follow-up of acalabrutinib in r/r cll
-
1:17
dr. woyach on treatment challenges in cll
-
1:46
dr. woyach on frontline treatment options in cll
-
1:21
dr. woyach on clinical trials examining novel triplets in cll
-
1:16
dr. woyach on ibrutinib and peripheral lymphocytosis in patients with chronic lymphocytic leukemia
-
4:53
elevate tn: comparing acalabrutinib monotherapy or in combination with obinutuzumab in treatment...
-
1:28
dr. woyach on remaining sequencing questions in cll
-
0:52
42-month follow-up data of acalabrutinib monotherapy in r/r cll
-
1:22
combined acalabrutinib treatments for cll
-
1:17
dr. woyach discusses progression on ibrutinib with the acquisition of resistance mutations
-
1:37
woyach on the safety profiles of btk inhibitors in cll